A phase II protection study of BB-10010 in patients with high grade non-Hodgkin's lymphoma undergoing intensive chemotherapy.

International journal of oncology

Volumn 22, Issue 2, 2003, Pages 421-424

  Hough, R E ^a   Lorigan, P C ^a   Poynton, C ^a   Newland, A ^a   Gupta, R K ^a   Foran, J ^a   Hancock, B W ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH INHIBITOR; MACROPHAGE INFLAMMATORY PROTEIN 1;

ADULT; AGED; ARTICLE; CELL DIVISION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; FEMALE; GROWTH INHIBITORS; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOMA, HIGH-GRADE; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, T-CELL; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; MIDDLE AGED; NEUTROPENIA; SAFETY; THROMBOCYTOPENIA; TREATMENT FAILURE;

MLCS; MLOWN;

EID: 0043020621     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.22.2.421     Document Type: Article

References (0)